Tri Locum Partners LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001826434

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 18 positions · Total reported value $506.14M · Top-10 concentration 80.1% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 90.9% · 3 new · 13 cut · 4 exited

Active Share (vs S&P 500): 97.4% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -1.6% · vs SPY -3.7% · Prev Value $813.22M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): +2.1% · vs SPY -0.0% · Latest Value $506.14M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Tri Locum Partners LP disclosed 18 equity positions with a combined reported value of $506.14M. The filing implies a focused portfolio: its ten largest positions account for 80.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were VRTX ($69.48M), LLY ($59.03M), TEVA ($48.46M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Tri Locum Partners LP opened 3 new positions, trimmed 13 and fully exited 4, a turnover rate of 90.9% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q3 2026 were AMRX ($46.86M), CELC ($16.11M), VRDN ($1.86M).

Of the 4 positions fully exited versus the prior quarter, the largest were TARS ($20.67M), ISRG ($19.08M), CYTK ($16.53M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • AMRX AMNEAL PHARMACEUTICALS INC · $46.86M
  • CELC CELCUITY INC · $16.11M
  • VRDN VIRIDIAN THERAPEUTICS INC · $1.86M

Fully Exited (vs previous quarter)

  • TARS TARSUS PHARMACEUTICALS INC · prev qtr: $20.67M
  • ISRG INTUITIVE SURGICAL INC · prev qtr: $19.08M
  • CYTK CYTOKINETICS INC · prev qtr: $16.53M
  • BBNX BETA BIONICS INC · prev qtr: $7.73M

Insider Transactions (Form 4)

Latest Tri Locum Partners LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Tri Locum Partners LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 18 positions worth $506.14M in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-119074 (status: Approved), registered 2020-07-16
  • Regulatory AUM (Form ADV): $1.09B as of 2026-04-06
  • Client mix (by RAUM): pension and profit-sharing plans 64%, sovereign wealth funds 36%
  • Manages 1 private funds, of which 1 hedge funds

Portfolio Structure

  • 18 positions · $506.14M reported value (Q3 2026)
  • Top 10 holdings = 80.1% of reported value
  • Largest position: VRTX (VERTEX PHARMACEUTICALS INC) at 13.7%
  • Average position size: $28.12M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 2 added, 13 reduced, 4 exited

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund reduced exposure to large-cap healthcare names (e.g., VRTX, LLY, JNJ) while adding smaller/mid-cap positions (TEVA, AMRX), suggesting a tactical shift toward undervalued or high-growth healthcare sub-sectors, possibly anticipating volatility or rotation. 2. Key moves: - Reduced: VRTX (-34.1% shares), LLY (-33.3%), DXCM (-40.4%), JAZZ (-27.7%), ARGX (-26.9%), ASND (-54.2%), AXSM (-34.6%), JNJ (-82.7%). - Added: TEVA (+63.9% shares), AMRX (new position). 3. Portfolio structure: Active, healthcare-focused (100% sector), with moderate risk appetite (mix of large/mid-caps, some high-beta names like ASND/AXSM). 4. Per-holding one-liner: - VRTX: Vertex Pharmaceuticals (cystic fibrosis drugs). - LLY: Eli Lilly (diabetes/obesity drugs). - TEVA: Teva Pharmaceuticals (generic drugs). - AMRX: Amneal Pharmaceuticals (generic/specialty drugs). - DXCM: Dexcom (diabetes monitoring devices). - JAZZ: Jazz Pharmaceuticals (sleep disorders/oncology). - ARGX: Argenx (immunology/autoimmune therapies). - ASND: Ascendis Pharma (growth hormone deficiency). - AXSM: Axsome Therapeutics (CNS disorders). - JNJ: Johnson & Johnson (diversified healthcare). 5. Style summary: The fund rotated out of large-cap healthcare staples into smaller/mid-cap biotechs/generics, indicating a tactical tilt toward higher-growth, undervalued names within healthcare.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 05:09

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 132.90K $69.48M 13.73%
13.73%
Reduce
2 51.02K $59.03M 11.66%
11.66%
Reduce
3 1.22M $48.46M 9.57%
9.57%
Add
4 2.33M $46.86M 9.26%
9.26%
New
5 489.40K $42.23M 8.34%
8.34%
Reduce
6 160.32K $37.12M 7.33%
7.33%
Reduce
7 30.40K $29.15M 5.76%
5.76%
Reduce
8 118.38K $26.97M 5.33%
5.33%
Reduce
9 143.34K $26.43M 5.22%
5.22%
Reduce
10 73.56K $19.47M 3.85%
3.85%
Reduce
11 410.24K $18.81M 3.71%
3.71%
Reduce
12 33.00K $17.88M 3.53%
3.53%
Reduce
13 33.67K $16.97M 3.35%
3.35%
Reduce
14 202.62K $16.11M 3.18%
3.18%
New
15 177.22K $15.60M 3.08%
3.08%
Add
16 40.02K $8.21M 1.62%
1.62%
Reduce
17 144.41K $5.50M 1.09%
1.09%
Reduce
18 90.11K $1.86M 0.37%
0.37%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 80% R 80% F1 80% (modelled on 2026-Q2; 8/10 hit)

Low-confidence forecast This fund replaces about 49% of its Top-10 each quarter and backtests at F1 52% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 52% · recall 52% · F1 52% · avg rank error 4.0 · Top-10 turnover 49%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 30% 30% 30% ABBV · TEVA · KVUE · GEHC · REGN · ASND · BIIB · CTLT · AVDL · XENE TEVA · AVDL · SILK · NTRA · ASND · LEGN · MRK · VRTX · MDGL · BAX
2024-Q2 40% 40% 40% TEVA · SILK · AVDL · LEGN · ASND · NTRA · MDGL · MRK · VRTX · BAX TEVA · ARGX · ASND · AMGN · NTRA · AXSM · INSM · MRUS · REGN · MDGL
2024-Q3 40% 40% 40% TEVA · ARGX · ASND · AXSM · NTRA · AMGN · INSM · MDGL · MRUS · INSP PFE · TEVA · NTRA · STVN · ARGX · INSP · PCVX · AVDL · UTHR · LEGN
2024-Q4 70% 70% 70% PFE · TEVA · NTRA · STVN · ARGX · INSP · PCVX · AVDL · UTHR · VRNA TEVA · ZBH · ARGX · NTRA · INSP · STVN · AXSM · VRNA · AVDL · BMY
2025-Q1 40% 40% 40% TEVA · ZBH · ARGX · NTRA · INSP · STVN · AXSM · VRNA · AVDL · NVO CI · MCK · SLNO · TEVA · INSP · MDGL · AXSM · ARGX · GILD · ILMN
2025-Q2 60% 60% 60% CI · MCK · SLNO · TEVA · AXSM · MDGL · INSP · GILD · ARGX · ILMN TEVA · MDGL · ALNY · ARGX · ASND · SLNO · VRNA · INSP · UNH · AXSM
2025-Q3 50% 50% 50% TEVA · MDGL · ALNY · ARGX · ASND · SLNO · UNH · INSP · VRNA · AXSM JNJ · UTHR · MRK · AXSM · ASND · VERA · ARGX · MDGL · SLNO · ABBV
2025-Q4 50% 50% 50% UTHR · JNJ · MRK · AXSM · ASND · VERA · ARGX · MDGL · SLNO · ABBV JNJ · DHR · LLY · UTHR · ASND · MDGL · BSX · TEVA · IONS · VERA
2026-Q1 50% 50% 50% JNJ · DHR · LLY · UTHR · ASND · MDGL · BSX · TEVA · VERA · IONS JNJ · ISRG · TMO · ASND · VRTX · LLY · MDGL · DXCM · UTHR · NUVL
2026-Q2 60% 60% 60% JNJ · ISRG · TMO · ASND · VRTX · MDGL · LLY · DXCM · UTHR · NUVL JNJ · VRTX · LLY · ASND · DXCM · AXSM · JAZZ · ELVN · ARGX · MDGL
2026-Q3 ★ 80% 80% 80% VRTX · JNJ · LLY · ASND · DXCM · AXSM · JAZZ · ELVN · ARGX · MDGL VRTX · LLY · TEVA · AMRX · DXCM · JAZZ · ARGX · ASND · AXSM · JNJ

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings8 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return+4.48%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+21.49%vs benchmark
Barra annualised vol21.4%Model estimate
Realised vol22.5%Annualised in window
Weighted beta0.39Raw exposure
Factor / specific risk65% / 35%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.185.793.2100.7108.210-0110-2311-16Tri Locum Partners LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)+4.48%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+21.49%Portfolio − benchmark
Arithmetic return sum+4.71%Difference vs compounded is the cross term
Weighted raw beta0.39Weighted holding betas
Realised volatility (annualised)22.54%Daily returns in window
Barra model volatility (annualised)21.44%Factor + specific
Factor share of variance64.8%Barra factors
Specific share of variance35.2%Stock residuals
Reported value$262.4M13F long US equity

2. Return attribution

The +4.71% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +2.36% 50.2%
Momentum & Growth 3 -2.13% -45.2%
Volatility & Tail Risk 7 +2.40% 50.9%
Industry 12 +6.98% 148.4%
Specific 1 -4.91% -104.4%
Return attribution (style + industry, %)-7.5-3.8+0.0+3.8+7.5Growth-0.15Short-term Reversal+0.18Mid Cap-0.21Size+0.28Leverage (Downside Vol)+0.75Max Drawdown-1.30Residual Volatility+1.60Momentum-2.15Turnover+2.17Beta-2.19Kurtosis+2.41Skewness-3.20Historical Volatility+4.33Health Care+6.98
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +1.00 +6.98% +6.98% 148.4%
Historical Volatility Style -0.31 -14.00% +4.33% 91.9%
Kurtosis Style +0.32 +7.51% +2.41% 51.2%
Turnover Style -0.45 -4.80% +2.17% 46.1%
Residual Volatility Style +0.49 +3.29% +1.60% 34.0%
Leverage (Downside Vol) Style -0.44 -1.71% +0.75% 15.9%
Size Style -0.15 -1.95% +0.28% 6.0%
Short-term Reversal Style +0.20 +0.87% +0.18% 3.7%
Amihud Illiquidity Style -0.13 -0.45% +0.06% 1.3%
Growth Style -0.09 +1.75% -0.15% -3.2%
Mid Cap Style +0.11 -1.94% -0.21% -4.5%
Max Drawdown Style +0.74 -1.76% -1.30% -27.6%
Momentum Style +0.54 -4.00% -2.15% -45.7%
Beta Style -0.49 +4.44% -2.19% -46.5%
Skewness Style +0.73 -4.39% -3.20% -68.0%
Specific Specific — — -4.91% -104.4%

3. Risk attribution

Annualised volatility is 21.44%; factor risk explains 64.8% of variance and specific risk 35.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-57.0-28.5+0.0+28.5+57.0Beta-2.24Residual Volatility-0.69Turnover-0.35Amihud Illiquidity+0.30Size+0.78Leverage (Downside Vol)+1.30Kurtosis+1.35Short-term Reversal+1.44Max Drawdown+1.78Historical Volatility+3.29Momentum+5.19Specific+35.18Health Care+52.79
Factor Type Exposure Share of variance Vol contribution Share of vol
Health Care Industry +1.00 52.8% +11.32% 11.3%
Specific Specific — 35.2% +7.54% 7.5%
Momentum Style +0.54 5.2% +1.11% 1.1%
Historical Volatility Style -0.31 3.3% +0.70% 0.7%
Max Drawdown Style +0.74 1.8% +0.38% 0.4%
Short-term Reversal Style +0.20 1.4% +0.31% 0.3%
Kurtosis Style +0.32 1.4% +0.29% 0.3%
Leverage (Downside Vol) Style -0.44 1.3% +0.28% 0.3%
Size Style -0.15 0.8% +0.17% 0.2%
Amihud Illiquidity Style -0.13 0.3% +0.06% 0.1%
Turnover Style -0.45 -0.3% -0.08% -0.1%
Residual Volatility Style +0.49 -0.7% -0.15% -0.1%
Beta Style -0.49 -2.2% -0.48% -0.5%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.71.62.4Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.15 +2.10 -2.25
Non-linear Size +0.04 +1.68 -1.64
Mid Cap +0.11 +0.13 -0.02
Beta -0.49 +1.29 -1.79
Momentum +0.54 +0.72 -0.18
Short-term Reversal +0.20 -0.64 +0.84
Residual Volatility +0.49 -0.40 +0.89
Historical Volatility -0.31 +0.86 -1.17
Liquidity +0.06 +0.11 -0.06
Amihud Illiquidity -0.13 +1.16 -1.29
Turnover -0.45 +0.21 -0.66
Growth -0.09 +0.58 -0.67
Leverage (Downside Vol) -0.44 +0.14 -0.58
Skewness +0.73 +0.24 +0.49
Kurtosis +0.32 +0.21 +0.11
Max Drawdown +0.74 -0.08 +0.82

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Health Care 100.0% 1.7% +4.60% +8.29% +24.98% -0.06% -3.62% +4.45%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Total +23.98% +15.78% -19.47% +20.29%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
VRTX VERTEX PHARMACEUTICALS INC Health Care 26.48% +2.86% +0.76% Reduce
LLY ELI LILLY & CO Health Care 22.49% +23.73% +5.34% Reduce
DXCM DEXCOM INC Health Care 16.09% -5.42% -0.87% Reduce
ARGX ARGENX SE Health Care 11.11% -0.83% -0.09% Reduce
JNJ JOHNSON & JOHNSON Health Care 7.42% +6.73% +0.50% Reduce
UTHR UNITED THERAPEUTICS CORP DEL Health Care 6.81% +8.49% +0.58% Reduce
MDGL MADRIGAL PHARMACEUTICALS INC Health Care 6.47% -15.87% -1.03% Reduce
RVMD REVOLUTION MEDICINES INC Health Care 3.13% -18.70% -0.58% Reduce
Contribution rank Symbol Sector Weight Return Contribution
1 LLY Health Care 22.49% +23.73% +5.34%
2 VRTX Health Care 26.48% +2.86% +0.76%
3 UTHR Health Care 6.81% +8.49% +0.58%
4 JNJ Health Care 7.42% +6.73% +0.50%
5 ARGX Health Care 11.11% -0.83% -0.09%
6 RVMD Health Care 3.13% -18.70% -0.58%
7 DXCM Health Care 16.09% -5.42% -0.87%
8 MDGL Health Care 6.47% -15.87% -1.03%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +4.48%, versus -17.01% for the QQQ synthetic benchmark — an excess of +21.49%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +6.98%, Historical Volatility +4.33%, Kurtosis +2.41%; the largest drags came from Skewness -3.20%, Beta -2.19%, Momentum -2.15%. Specific (stock-level) return contributed -4.91%.
  3. Risk attribution: Barra model volatility is 21.44% annualised; factor risk explains 65% of variance and specific risk 35%. The largest factor risk sources are Health Care 52.8%, Momentum 5.2%, Historical Volatility 3.3%.
  4. Style tilt: size -0.15, momentum +0.54, volatility -0.31, liquidity +0.06; the weighted raw beta is 0.39. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.78% and interaction -19.47%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Tri Locum Partners LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Tri Locum Partners LP reported 18 equity positions worth $506.14M in aggregate; its largest disclosed positions were VRTX ($69.48M), LLY ($59.03M), TEVA ($48.46M).

How large is Tri Locum Partners LP's portfolio?

Tri Locum Partners LP reported $506.14M of long equity holdings across 18 positions as of 2026-Q3. Top-10 holdings account for 80.1% of reported value.

What is Tri Locum Partners LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/tri-locum-partners/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →